Aldeyra Therapeutics Insider Buys Stock Amid Regulatory Progress

Aldeyra Therapeutics' Principal Financial Officer, Michael Alfieri, has purchased 2,500 shares of the company's stock, valued at $13,250, showing confidence in the company's future prospects. The FDA accepted the resubmitted New Drug Application for reproxalap, a potential treatment for dry eye disease, with a target action date set for December 16, 2025. Analysts have noted the company's strong cash reserves and strategic board appointments as positive factors, but concerns remain about its financial health and technical indicators.